Sutherlandia frutescens is a well-known South African herbal remedy traditionally used for stomach problems, internal cancers, diabetes, various inflammatory conditions and recently to improve the overall health in cancer and HIV/AIDS patients. The influence of crude Sutherlandia frutescens extracts (prepared with 70% ethanol) was investigated on cell numbers, morphology, and gene expression profiles in a MCF-7 human breast adenocarcinoma cell line. Time-dependent (24, 34, 48 and 72 h) and dose-dependent (0.5-2.5 mg/ml) studies were conducted utilizing spectrophotometrical analysis with crystal violet as DNA stain. A statistically significant decrease to 50% of malignant cell numbers was observed after 24 h of exposure to 1.5 mg/ml Sutherlandia frutescens extract when compared to vehicle-treated controls. Morphological characteristics of apoptosis including cytoplasmic shrinking, membrane blebbing and apoptotic bodies were observed after 24 h of exposure. A preliminary global gene expression profile was o op pe en nU UP P ( (J Ju un ne e 2 20 00 07 7) ) obtained by means of microarray analysis and revealed valuable information about the molecular mechanisms and signal transduction associated with 70% ethanolic Sutherlandia frutescens extracts.
Introduction
Sutherlandia frutescens (unwele in Zulu; kankerbos in Afrikaans; cancerbush in English)
is a well-known multi-purpose medicinal plant in Southern Africa and has enjoyed a long history of use by many cultures in Southern Africa as a tonic for diverse health conditions o op pe en nU UP P ( (J Ju un ne e 2 20 00 07 7) ) (Van Wyk and Gericke, 2000) . Traditionally it is a popular remedy for stomach problems, internal cancers, diabetes and various inflammatory conditions ( Van Wyk et al., 1997) . Decoctions prepared by the Khoi and Nama people of South Africa are used externally to wash wounds and internally for fevers and as a tonic ( Van Wyk and Gericke, 2000) . Tai et al. (2004) revealed that ethanolic leaf extracts exhibited concentration-dependent antiproliferative activities in vitro on several human cancer cell lines including the MCF-7 cell line. Fernandes et al. (2004) described the antioxidant potential of this multi-purpose plant and concluded that Sutherlandia frutescens leaf extracts possess significant superoxide, as well as hydrogen peroxide scavenging properties. Antioxidant compounds have been shown to act on modifying immune mechanisms by modulating activity and production of cytotoxic immune cells, thus enhancing the expression of cancer suppressor genes and inhibiting tumor angiogenesis.
This partly explains the anticancer effect observed in some cancers according to preliminary clinical evidence (Shklar, 1998 and Gericke et al., 2001 ).
In a study conducted by Tai et al. (2004) , it was found that the leaves of the Sutherlandia frutescens plant contain several biological active chemicals including l-canavanine, pinitol, gamma-aminobutyric acid, methyl and propyl parabens, saponins, as well as several chemicals with unknown effects on human physiology including sigma-4-en-3-one and gamma-sitosterol. l-Canavanine, a natural l-arginine analog and its metabolite, canaline, exert antitumor properties (Berjis and Green, 1986 , Swaffar et al., 1995 and Jang et al., 2002 and are likely two of many factors contributing to the in vitro antiproliferative and apoptotic activity of Sutherlandia frutescens. Chinkwo (2005) demonstrated that Sutherlandia frutescens extracts induced apoptosis in three different cell lines (CHO, Caski and Jurkat T lymphoma cells) and it was suggested that apoptosis occurred as a result of flip-flop translocation of phosphatidyl serine.
An advantage for the use of Sutherlandia frutescens as an adaptogenic tonic includes its relative safety with the only known side effects being occasional mild diarrhea, dry mouth, mild diuresis and dizziness in cachectic patients (Mills et al., 2005) . In a 3-month toxicity study of oral Sutherlandia frutescens leaf powder conducted on vervet monkeys, o op pe en nU UP P ( (J Ju un ne e 2 20 00 07 7) ) it was revealed that quantities up to nine times the recommended dose of 9 mg/(kg day)
were safe for consumption with no side effects (Medical Research Council and National Research Foundation of South Africa, 2002) . Sutherlandia frutescens is also relatively economical to acquire. The use of traditional medicine for the treatment of various maladies in many parts of Africa is an inherent characteristic of the continent. However, the precise nature and mechanism of ethanolic extracts of Sutherlandia frutescens and its antiproliferative and apoptotic properties need to be fully investigated to support the use of traditional medicine as an alternative to often-expensive conventional medicine.
It has been previously commented that the bioactivity of Sutherlandia frutescens might be as a result of synergistic effects of compounds present in Sutherlandia frutescens extracts and that the bioactivity of the extracts may not be solely dependent on a single compound, rather a host of phytocompounds resulting in a relatively complex mechanism of action (Tai et al., 2004) . The aim of the study was to investigate the influence of to obtain a stock solution concentration of 100 mg/ml and extracted for 24 h at room temperature. After extraction, the supernatant was transferred to a 50 ml tube and centrifuged at 3000 rpm for 5 min to further remove any debris. The supernatant was filtered twice with a 0.22 μm filter to obtain a purified 100 mg/ml stock solution.
Determination of cell numbers
Five thousand MCF-7 cells were seeded per well in 96-well plates. Cells were cultured for 24 h to allow for attachment. After growth medium had been replaced, cells were exposed to Sutherlandia frutescens concentrations ranging from 0.5 to 2.5 mg/ml, as well as vehicle controls, respectively for 72 h in order to determine the Sutherlandia frutescens concentration responsible for causing 50% inhibition of cell growth (IC 50 ).
Subsequently a time-dependent study with intervals of 24, 36, 48 and 72 h were conducted with the IC 50 concentration and vehicle-treated control, respectively. Cell numbers were determined spectrophotometrically with crystal violet as a DNA stain (Joubert et al., 2003) .
Statistics
Data obtained from independent experiments are shown as the mean ± S.D. and were statistically analyzed for significance using the analysis of variance-single factor model followed by a two-tailed Student's t-test. Means are presented in bar charts, with T-bars o op pe en nU UP P ( (J Ju un ne e 2 20 00 07 7) ) referring to standard deviations. P-values <0.05 were regarded as statistically significant and indicated by an * or number as indicated in the legends.
Cell morphology
Two hundred and fifty thousand MCF-7 cells were seeded onto heat-sterilized coverslips in six-well plates and allowed to attach as described above and subsequently exposed to 1.5 mg/ml of Sutherlandia frutescens extract for periods of 24, 36, 48 and 72 h at 37 °C.
Cells were fixed in Bouin's fixative for 20 min and stained by standard haematoxylin and eosin staining procedures (Lillie, 1965) . 
Microarray data analysis
Spotfinding was performed using Genepix (Molecular Devices Corporation, Sunnyvale, CA, USA). Background correction, filtering and normalization were performed using the Linear Models for Microarray Data (LIMMA) module in Bioconductor. Background subtraction was used and spots flagged as problematic in Genepix were zero-weighted.
Global Loess normalization was performed within arrays. Least-squares fitting was used for the linear model calculation. Mapping of genes to metabolic pathways and Gene Ontology (GO) categories was performed using FATIGO.
Results

Determination of cell numbers
The antiproliferative effects of ethanolic plant extracts from Sutherlandia frutescens were determined by crystal violet DNA staining assays. The dosage of the ethanol plant extract required to statistically significantly inhibit 50% of MCF-7 cell-proliferation (IC 50 ) after 24 h of exposure was found to be 1.5 mg/ml compared to the vehicle-treated control. A time-dependent study over 72 h with intervals of 24, 36, 48 and 72 h was conducted with the IC 50 concentration and revealed a similar pattern of 40-50% growth inhibition over the entire period of the experiment compared to the cells propagated in growth medium (Fig. 1A-D) . 
Cell morphology
Differences in cell densities between the vehicle-treated ( Fig. 2A) and Sutherlandia frutescens-treated (Fig. 2B ) cells were observed after 24 h of exposure (100× magnification). At a higher magnification (400×), the vehicle-treated control (Fig. 2C) exhibited a normal distribution of cells in mitosis and a majority of cells in interphase. In contrast to the vehicle-treated control, Sutherlandia frutescens-treated cells showed morphological hallmarks of apoptosis (Fig. 2D) . The amount of cells revealing apoptotic characteristics was increased with prolonged exposure times of 36, 48 and 72 h to Sutherlandia frutescens leading to a further decrease in cell density (data not shown). 
Mitotic indices
frutescens-treated cells (2.0%). An increased occurrence of apoptosis was observed with
Sutherlandia frutescens-treated cells with 3.0% of cells exhibiting morphological hallmarks of apoptosis in comparison to vehicle-treated cells exhibiting 0.5% apoptotic cells (Fig. 3) . As already mentioned, the amount of cells revealing apoptotic characteristics was increased with prolonged exposure times of 36, 48 and 72 h to Sutherlandia frutescens leading to a further decrease in cell density (data not shown). 
Preliminary gene expression profile in MCF-7 cells in response to Sutherlandia frutescens treatment
Agilent's Human 1A Oligonucleotide Microarray slides with 20 173 known human 60-mer oligonucleotide probes were employed to collect genomic information on the mechanism of action of Sutherlandia frutescens extracts in MCF-7 cells.
Results obtained were normalized and analyzed with the Linear Models for Microarray
Data (LIMMA) analysis package (Smyth, 2005) . A summary of the preliminary list of specific genes and gene clusters with a P-value <0.01 and B-value of >1.2 is represented in Table 1 . In total 345 genes were statistically significantly (P < 0.01, B > 1.2) differentially expressed (Fig. 4) . The M-value is the mean log-expression over all the arrays in the experiment and the B-statistic is the log-odds of the gene that is differentially expressed (Smyth, 2005) . o op pe en nU UP P ( (J Ju un ne e 2 20 00 07 7) ) 
Discussion and conclusions
In and NF-κB signaling (Stephanou and Latchman, 2003 , Marchesini et al., 2004 , Wajant, 2004 , Liu et al., 2005 and Robinson et al., 2006 . Signal transducer and activator of transcription 1 (STAT-1) regulates apoptosis by inducing pro-apoptotic regulatory genes, as well as inhibiting NF-κB activation (Battle and Frank, 2002) . STAT-1 enhances p53 stability by inhibiting the MDM2 gene, the major factor that controls p53
proteasomal degradation and also associates with p53 to enhance p53-mediated gene activity and apoptosis (Stephanou and Latchman, 2003) . PIAS1 protein interacts with STAT-1 to suppress its DNA-binding activity (Greenhalgh and Hilton, 2001 ). Expression of the PIAS1 gene was found to be downregulated in Sutherlandia frutescens-treated cells compared to the vehicle-treated control. The effects of decreased intracellular levels of PIAS1 proteins on STAT-1 activity in MCF-7 cells provide a possible mechanism for induction of apoptosis.
Research has shown (Chinkwo, 2005) that Sutherlandia frutescens extracts induced DNA fragmentation in a similar fashion to known inducers such as ceramide. Ceramide is a major sphingolipid metabolite and has been demonstrated to play an important role in cell cycle arrest and apoptosis. Ceramide mediates its effect by activating several kinases and phophatases involved in stress-signaling cascades (Pettus et al., 2002 and Ruvolo, 2003) .
The ability of ceramide to activate protein phophatases such as protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) can cause it to indirectly inhibit key components of pro-growth signaling such as protein kinase B/Akt and activated retinomablastoma proteins (Rb) (Ruvolo, 2003) . Intracellular generation of ceramide is derived from sphingomyelinase (SMase)-mediated hydrolysis of sphingomyelin.
Sphingomyelinases are rapidly activated by diverse stress stimuli and results in increased intracellular ceramide levels (Reynolds et al., 2004) . The neutral sphingomyelinase-2 (SMPD3) gene was found to be upregulated in Sutherlandia frutescens-treated cells o op pe en nU UP P ( (J Ju un ne e 2 20 00 07 7) ) compared to vehicle-treated control cells. MCF-7 cells overexpressing neutral sphingomyelinase-2 (nS-Mase-2) had increased endogenous ceramide levels and exhibited a significant decrease in growth (Marchesini et al., 2004) . In addition, ceramide has the ability to induce downregulation of the proto-oncogene, c-myc (Wolff and Dobrowsky, 1994) and from the microarray data it can be seen that the MYC2L gene expression was downregulated. This study therefore suggests that the formation of ceramide might play a central role in the growth inhibitory effects of Sutherlandia frutescens extracts on MCF-7 cells.
Other interesting findings in the expression data revealed the downregulation of several gene expression profiles revealed target molecules influenced by these extracts, thus contributing to the unraveling of the in vitro molecular mechanisms and signal transduction associated with 70% ethanolic Sutherlandia frutescens extracts, providing a basis for further research on this multi-purpose medicinal plant in Southern Africa.
